Ignite Creation Date:
2025-12-25 @ 1:24 AM
Ignite Modification Date:
2026-03-09 @ 7:50 AM
Study NCT ID:
NCT02269293
Status:
COMPLETED
Last Update Posted:
2021-04-23
First Post:
2014-10-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-10-13
Start Date Type:
ACTUAL
Primary Completion Date:
2021-04-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-04-20
Completion Date Type:
ACTUAL
First Submit Date:
2014-10-14
First Submit QC Date:
None
Study First Post Date:
2014-10-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-04-22
Last Update Post Date:
2021-04-23
Last Update Post Date Type:
ACTUAL